RxDoctor Payments Data

Letitia Lincecum

Family · Alexandria, LANPI 1346655289

Payments from drug & device makers

$2,106in general payments, 2019–2025

Across 81 payments — averaging $26.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$526
  • Abbott$385
  • Ardelyx, Inc.$310
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$241
  • Edwards Lifesciences$162
  • Johnson & Johnson$146
  • plus $336 from 8 others

What the payments were for

  • Food & beverage$2,106100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,106 in reported general payments places this provider in the 75th percentile of 3,610 family providers in Louisiana.

See all family providers in Louisiana

Medicare billing

Part B allowed, 2024
$10,437
Medicare patients
143
Services billed
198

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XifaxanRifaximin22$68,875
LinzessLinaclotide32$16,974
Sucralfate13$2,204
Balsalazide Disodium14$2,164
Lactulose13$594
Albuterol Sulfate HfaAlbuterol Sulfate23$572
Dicyclomine Hcl36$497
Ipratropium Bromide18$382
Cefdinir34$357
Fluticasone Propionate35$345
Ondansetron OdtOndansetron26$271
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst21$213
Mupirocin31$199
Gabapentin17$177
Methocarbamol29$170

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$241$68,87522 claims
AbbVieLinzess$526$16,97432 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 3,610 family providers in Louisiana.

Other family in Alexandria

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →